Biotechnology
Build Your Comparison
Side-by-side financial analysisStock Comparison
BMEA vs NTRA vs JPM
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Diagnostics & Research
Banks - Diversified
BMEA vs NTRA vs JPM — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||
|---|---|---|---|
| Industry | Biotechnology | Medical - Diagnostics & Research | Banks - Diversified |
| Market Cap | $70M | $30.37B | $896.00B |
| Revenue (TTM) | $0.00 | $2.50B | $280.33B |
| Net Income (TTM) | $-45M | $-226M | $57.05B |
| Gross Margin | — | 65.2% | 60.0% |
| Operating Margin | — | -13.0% | 25.9% |
| Forward P/E | — | — | 14.4x |
| Total Debt | $2M | $214M | $942.38B |
| Cash & Equiv. | $56M | $1.08B | $343.34B |
BMEA vs NTRA vs JPM — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Apr 21 | Jun 26 | Return |
|---|---|---|---|
| Biomea Fusion, Inc. (BMEA) | 100 | 6.9 | -93.1% |
| Natera, Inc. (NTRA) | 100 | 192.8 | +92.8% |
| JPMorgan Chase & Co. (JPM) | 100 | 208.5 | +108.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: BMEA vs NTRA vs JPM
Each card shows where this stock fits in a portfolio — not just who wins on paper.
BMEA is the clearest fit if your priority is sleep-well-at-night.
- Lower volatility, beta 1.78, Low D/E 5.4%, current ratio 5.23x
- 65.4% revenue growth vs JPM's 3.3%
NTRA is the clearest fit if your priority is growth exposure and long-term compounding.
- Rev growth 35.9%, EPS growth 0.7%, 3Y rev CAGR 41.1%
- 17.3% 10Y total return vs JPM's 465.8%
- +29.0% vs BMEA's -55.2%
JPM carries the broadest edge in this set and is the clearest fit for income & stability and defensive.
- Dividend streak 15 yrs, beta 0.94, yield 1.9%
- Beta 0.94, yield 1.9%, current ratio 0.52x
- Better valuation composite
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 65.4% revenue growth vs JPM's 3.3% | |
| Value | Better valuation composite | |
| Quality / Margins | 20.4% margin vs NTRA's -9.0% | |
| Stability / Safety | Beta 0.94 vs BMEA's 1.78 | |
| Dividends | 1.9% yield; 15-year raise streak; the other 2 pay no meaningful dividend | |
| Momentum (1Y) | +29.0% vs BMEA's -55.2% | |
| Efficiency (ROA) | 1.3% ROA vs BMEA's -77.1% |
BMEA vs NTRA vs JPM — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
BMEA vs NTRA vs JPM — Financial Metrics
Side-by-side numbers across 3 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
JPM leads this category, winning 3 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
JPM and BMEA operate at a comparable scale, with $280.3B and $0 in trailing revenue. JPM is the more profitable business, keeping 20.4% of every revenue dollar as net income compared to NTRA's -9.0%.
| Metric | |||
|---|---|---|---|
| RevenueTrailing 12 months | $0 | $2.5B | $280.3B |
| EBITDAEarnings before interest/tax | -$66M | -$313M | $81.4B |
| Net IncomeAfter-tax profit | -$45M | -$226M | $57.0B |
| Free Cash FlowCash after capex | -$56M | $92M | $100.9B |
| Gross MarginGross profit ÷ Revenue | — | +65.2% | +60.0% |
| Operating MarginEBIT ÷ Revenue | — | -13.0% | +25.9% |
| Net MarginNet income ÷ Revenue | — | -9.0% | +20.4% |
| FCF MarginFCF ÷ Revenue | — | +3.7% | +36.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +38.8% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +78.8% | -20.0% | +16.0% |
Valuation Metrics
JPM leads this category, winning 2 of 4 comparable metrics.
Valuation Metrics
| Metric | |||
|---|---|---|---|
| Market CapShares × price | $70M | $30.4B | $896.0B |
| Enterprise ValueMkt cap + debt − cash | $15M | $29.5B | $1.50T |
| Trailing P/EPrice ÷ TTM EPS | -0.99x | -139.52x | 16.00x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | 14.40x |
| PEG RatioP/E ÷ EPS growth rate | — | — | 0.90x |
| EV / EBITDAEnterprise value multiple | — | — | 18.36x |
| Price / SalesMarket cap ÷ Revenue | — | 13.17x | 3.20x |
| Price / BookPrice ÷ Book value/share | 2.07x | 16.93x | 2.47x |
| Price / FCFMarket cap ÷ FCF | — | 278.35x | 8.88x |
Profitability & Efficiency
JPM leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
JPM delivers a 15.9% return on equity — every $100 of shareholder capital generates $16 in annual profit, vs $-197 for BMEA. BMEA carries lower financial leverage with a 0.05x debt-to-equity ratio, signaling a more conservative balance sheet compared to JPM's 2.60x. On the Piotroski fundamental quality scale (0–9), NTRA scores 5/9 vs BMEA's 3/9, reflecting solid financial health.
| Metric | |||
|---|---|---|---|
| ROE (TTM)Return on equity | -196.7% | -15.1% | +15.9% |
| ROA (TTM)Return on assets | -77.1% | -10.4% | +1.3% |
| ROICReturn on invested capital | — | -36.1% | +4.5% |
| ROCEReturn on capital employed | -153.8% | -18.3% | +8.9% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 5 | 5 |
| Debt / EquityFinancial leverage | 0.05x | 0.13x | 2.60x |
| Net DebtTotal debt minus cash | -$54M | -$862M | $599.0B |
| Cash & Equiv.Liquid assets | $56M | $1.1B | $343.3B |
| Total DebtShort + long-term debt | $2M | $214M | $942.4B |
| Interest CoverageEBIT ÷ Interest expense | — | -34.29x | 0.74x |
Total Returns (Dividends Reinvested)
NTRA leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in JPM five years ago would be worth $21,820 today (with dividends reinvested), compared to $569 for BMEA. Over the past 12 months, NTRA leads with a +29.0% total return vs BMEA's -55.2%. The 3-year compound annual growth rate (CAGR) favors NTRA at 62.4% vs BMEA's -69.2% — a key indicator of consistent wealth creation.
| Metric | |||
|---|---|---|---|
| YTD ReturnYear-to-date | -12.7% | -7.3% | -0.5% |
| 1-Year ReturnPast 12 months | -55.2% | +29.0% | +21.8% |
| 3-Year ReturnCumulative with dividends | -97.1% | +328.7% | +138.2% |
| 5-Year ReturnCumulative with dividends | -94.3% | +104.4% | +118.2% |
| 10-Year ReturnCumulative with dividends | -93.1% | +1731.3% | +465.8% |
| CAGR (3Y)Annualised 3-year return | -69.2% | +62.4% | +33.6% |
Risk & Volatility
JPM leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
JPM is the less volatile stock with a 0.94 beta — it tends to amplify market swings less than BMEA's 1.78 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. JPM currently trades 95.1% from its 52-week high vs BMEA's 38.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||
|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.78x | 1.24x | 0.94x |
| 52-Week HighHighest price in past year | $3.08 | $256.36 | $337.25 |
| 52-Week LowLowest price in past year | $0.87 | $131.81 | $262.71 |
| % of 52W HighCurrent price vs 52-week peak | +38.0% | +82.7% | +95.1% |
| RSI (14)Momentum oscillator 0–100 | 38.2 | 55.9 | 59.1 |
| Avg Volume (50D)Average daily shares traded | 1.5M | 1.4M | 7.0M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: BMEA as "Buy", NTRA as "Buy", JPM as "Buy". Consensus price targets imply 1626.5% upside for BMEA (target: $20) vs 5.9% for JPM (target: $340). JPM is the only dividend payer here at 1.86% yield — a key consideration for income-focused portfolios.
| Metric | |||
|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $20.20 | $261.00 | $339.75 |
| # AnalystsCovering analysts | 13 | 27 | 61 |
| Dividend YieldAnnual dividend ÷ price | — | — | +1.9% |
| Dividend StreakConsecutive years of raises | — | — | 15 |
| Dividend / ShareAnnual DPS | — | — | $5.95 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +3.9% |
JPM leads in 4 of 6 categories (Income & Cash Flow, Valuation Metrics). NTRA leads in 1 (Total Returns).
BMEA vs NTRA vs JPM: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is BMEA or NTRA or JPM a better buy right now?
For growth investors, Natera, Inc.
(NTRA) is the stronger pick with 35. 9% revenue growth year-over-year, versus 3. 3% for JPMorgan Chase & Co. (JPM). JPMorgan Chase & Co. (JPM) offers the better valuation at 16. 0x trailing P/E (14. 4x forward), making it the more compelling value choice. Analysts rate Biomea Fusion, Inc. (BMEA) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — BMEA or NTRA or JPM?
Over the past 5 years, JPMorgan Chase & Co.
(JPM) delivered a total return of +118. 2%, compared to -94. 3% for Biomea Fusion, Inc. (BMEA). Over 10 years, the gap is even starker: NTRA returned +1731% versus BMEA's -93. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — BMEA or NTRA or JPM?
By beta (market sensitivity over 5 years), JPMorgan Chase & Co.
(JPM) is the lower-risk stock at 0. 94β versus Biomea Fusion, Inc. 's 1. 78β — meaning BMEA is approximately 88% more volatile than JPM relative to the S&P 500. On balance sheet safety, Biomea Fusion, Inc. (BMEA) carries a lower debt/equity ratio of 5% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.
04Which is growing faster — BMEA or NTRA or JPM?
By revenue growth (latest reported year), Natera, Inc.
(NTRA) is pulling ahead at 35. 9% versus 3. 3% for JPMorgan Chase & Co. (JPM). On earnings-per-share growth, the picture is similar: Biomea Fusion, Inc. grew EPS 69. 2% year-over-year, compared to 0. 7% for Natera, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — BMEA or NTRA or JPM?
JPMorgan Chase & Co.
(JPM) is the more profitable company, earning 20. 4% net margin versus -9. 0% for Natera, Inc. — meaning it keeps 20. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JPM leads at 26. 0% versus -13. 4% for NTRA. At the gross margin level — before operating expenses — NTRA leads at 64. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is BMEA or NTRA or JPM more undervalued right now?
Analyst consensus price targets imply the most upside for BMEA: 1626.
5% to $20. 20.
07Which pays a better dividend — BMEA or NTRA or JPM?
In this comparison, JPM (1.
9% yield) pays a dividend. BMEA, NTRA do not pay a meaningful dividend and should not be held primarily for income.
08Is BMEA or NTRA or JPM better for a retirement portfolio?
For long-horizon retirement investors, JPMorgan Chase & Co.
(JPM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 94), 1. 9% yield, +465. 8% 10Y return). Biomea Fusion, Inc. (BMEA) carries a higher beta of 1. 78 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (JPM: +465. 8%, BMEA: -93. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between BMEA and NTRA and JPM?
These companies operate in different sectors (BMEA (Healthcare) and NTRA (Healthcare) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: BMEA is a small-cap quality compounder stock; NTRA is a mid-cap high-growth stock; JPM is a large-cap deep-value stock. JPM pays a dividend while BMEA, NTRA do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.